'Equipment For Sale': Gaza Journalist Offers To Sell Press Shield To Feed His Starving Family
Gaza-based photojournalist Mohammed Abo Oun offered his camera equipment and press shield to feed his family as the enclave faces an acute hunger crisis due to Israel's offensive.
As the talks for a ceasefire in the ongoing Israel-Hamas war reached another roadblock, a Gaza-based photojournalist's plea to sell his equipment to buy food for his starving family has cast the spotlight on the growing humanitarian crisis and hunger in the besieged Palestinian enclave.
Israel has come under mounting international outrage over severe shortages of food, clean water and medical supplies in wake of its devastating offensive in retaliation for the Hamas-led attacks on October 7, 2023. The humanitarian crisis is now affecting aid workers and journalists as well.
In a LinkedIn post, journalist Mohammed Abo Oun has offered his camera equipment and press shield to buy food for himself and his family. His post has ignited global attention, reflecting a growing desperation among Gaza's population, who are staring at a devastating food scarcity.
'I am the photojournalist Mohammed Abu Aoun from Gaza, I want to offer my equipment and the press shield for sale so that I can buy food for me and my family," he said.
Abo Aoun has contributed to major international media outlets, including The New York Times, Sky News, and ABC News.
Gaza Facing Imminent Famine
The United Nations and NGOs are warning of an imminent famine in the Gaza Strip – a designation based on strict criteria and scientific evidence. 'A large proportion of the population of Gaza is starving", according to the World Health Organisation's chief, Tedros Adhanom Ghebreyesus.
Malnutrition-related deaths have surged this month, with even humanitarian workers struggling to obtain basic food supplies. Israel imposed a total blockade on the entry of aid into Gaza on March 2 after talks to extend a ceasefire broke down. It began to allow a trickle of aid to enter again in late May, but many groups warned that these steps are not enough to prevent the acute scarcity Gaza faces.
Humanitarian organisations have also accused the Israeli army of imposing excessive restrictions on the goods allowed into Gaza and on the routes made available to transport the aid to distribution points.
Israel-Hamas Ceasefire Talks
Furthermore, US President Donald Trump and Israeli Prime Minister Benjamin Netanyahu appeared to abandon Gaza ceasefire negotiations with Hamas on Friday, both saying it had become clear that the Palestinian militants did not want a deal.
'Hamas really didn't want to make a deal. I think they want to die. And it's very bad. And it got to be to a point where you're going to have to finish the job," Trump said, while Netanyahu said Israel was considering 'alternative" options to bring its hostages from Gaza.
'Trump's remarks are particularly surprising, especially as they come at a time when progress had been made on some of the negotiation files," Hamas official Taher al-Nunu told AFP.
(with inputs from agencies)
Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated!
tags :
gaza crisis Israel Hamas
Location :
Jerusalem, Israel
First Published:
July 26, 2025, 23:08 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
25 minutes ago
- Hans India
Mangaluru NGO inducted into WHO's Global Civil Society Commission
Mangaluru: Ina significant international recognition, Mangaluru-based Anti Pollution Drive Foundation (APDF) has been inducted into the Civil Society Commission of the World Health Organisation (WHO), joining a global network of organisations shaping the future of public health and environmental well-being. The Commission, created by WHO to strengthen collaboration with civil society actors, focuses on key areas including primary healthcare, gender rights, health equity, and community-based health interventions. APDF's membership was confirmed through a letter jointly signed by Commission co-chairs Ravi Ram and Lisa Hilmi. The Foundation was selected from a global pool of nearly 680 applicants after a multi-phase review and due diligence process by WHO. APD Foundation has earned a reputation for pioneering projects in air quality management, inclusive sanitation, and occupational health in urban settings. Its initiatives—such as Smart Swaccha Mangaluru (in partnership with UN-Habitat), Shuddha Gaali, and Waste Wise Cities—have combined grassroots activism with data-driven policy advocacy. Commenting on the milestone, APDF founder Abdullah A. Rehman said, 'This inclusion validates our approach of combining community action with evidence-based solutions. It also brings attention to how smaller cities like Mangaluru can be models of public health innovation.' The WHO Commission held its first annual general meeting in March 2024 and laid out a two-year action plan while forming three working groups to guide engagement with global civil society. APDF's induction is seen as a move towards diversifying voices in international forums and ensuring representation from cities outside of traditional urban centres.
Economic Times
3 hours ago
- Economic Times
Trump says he's cut drug prices by up to 1,500%. That's not possible
Synopsis Donald Trump claimed significant drug price cuts, even up to 1500%. Experts refute this, stating such cuts are impossible. They suggest it would mean people are paid to take medicine. The White House defended Trump, citing price differences with other nations. Trump also mentioned future price drops. Some drugmakers are open to cuts. AP Days after he sent letters instructing top pharmaceutical manufacturers to use a "most favored nation" pricing model for prescription drugs, President Donald Trump told reporters on Sunday that he had cut costs by up to 1,500%. But Trump's grandiose claim is mathematically impossible. Here's a closer look at the facts. TRUMP: "You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500%. I don't mean 50%, I mean 14 - 1,500%." THE FACTS: This is false. Cutting drug prices by more than 100% would theoretically mean that people are being paid to take medications. The Trump administration has taken steps to lower prescription drug prices, but experts say there's no indication costs have seen such a massive drop. Geoffrey Joyce, director of health policy at the University of Southern California's Schaeffer Center, called Trump's claim "total fiction" made up by the Republican president. He agreed that it would amount to drug companies paying customers, rather than the other way around. "I find it really difficult to translate those numbers into some actual estimates that patients would see at the pharmacy counter," said Mariana Socal, an associate professor of health policy and management at Johns Hopkins University who studies the U.S. pharmaceutical market. She added that Trump's math is "really hard to follow." Asked what Trump was using to back up his claim, White House spokesman Kush Desai said: "It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people." The White House provided a chart of price differentials for drugs in the U.S. and comparable countries, but did not offer any other evidence. On Sunday, Trump also described cuts to drug prices as a future development, not that already happened. "So we'll be dropping drug prices," he said. "It will start over the next two to three months by 1,200, 1,300 and even 1,400%." Prices for most prescription drugs - unbranded generics are the exception - are higher in the U.S. than they are in other high-income countries. This is in large part due to the way drug prices are negotiated in the United States. Trump made his recent appeal in letters to 17 pharmaceutical manufacturers, the White House announced last week. He asked them to reduce costs in the U.S. by matching the lowest prices of prescriptions drugs in other comparably developed countries. Some drugmakers have since indicated that they are open to cutting costs. This move follows an executive order Trump signed in May setting a 30-day deadline for drugmakers to electively lower prices in the U.S. or face new limits in the future over what the government will pay. The federal government has the most power to shape the price it pays for drugs covered by Medicare and Medicaid. It's unclear what - if any - impact the Trump administration's efforts will have on millions of Americans who have private health insurance. Socal pointed out that if drug manufacturers had cut costs to the extent Trump claims, they would be shouting it from the rooftops, especially given the heat they've taken over the years for their pricing practices. "My expectation would be that they would make announcements - public announcements - and that those announcements would come way in advance of the actual effective dates when those price cuts would come into effect," she said. Joyce agreed that there has been no indication of a substantial cut. "Not at all, not at all, none whatsoever," he said. "And let alone 1,500."
Time of India
3 hours ago
- Time of India
Trump says he's cut drug prices by up to 1,500%. That's not possible
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Days after he sent letters instructing top pharmaceutical manufacturers to use a "most favored nation" pricing model for prescription drugs, President Donald Trump told reporters on Sunday that he had cut costs by up to 1,500%.But Trump's grandiose claim is mathematically a closer look at the "You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500%. I don't mean 50%, I mean 14 - 1,500%."THE FACTS: This is false. Cutting drug prices by more than 100% would theoretically mean that people are being paid to take medications. The Trump administration has taken steps to lower prescription drug prices, but experts say there's no indication costs have seen such a massive Joyce, director of health policy at the University of Southern California 's Schaeffer Center, called Trump's claim "total fiction" made up by the Republican president. He agreed that it would amount to drug companies paying customers, rather than the other way around."I find it really difficult to translate those numbers into some actual estimates that patients would see at the pharmacy counter," said Mariana Socal, an associate professor of health policy and management at Johns Hopkins University who studies the U.S. pharmaceutical market. She added that Trump's math is "really hard to follow."Asked what Trump was using to back up his claim, White House spokesman Kush Desai said: "It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people."The White House provided a chart of price differentials for drugs in the U.S. and comparable countries, but did not offer any other evidence. On Sunday, Trump also described cuts to drug prices as a future development, not that already happened."So we'll be dropping drug prices," he said. "It will start over the next two to three months by 1,200, 1,300 and even 1,400%."Prices for most prescription drugs - unbranded generics are the exception - are higher in the U.S. than they are in other high-income countries. This is in large part due to the way drug prices are negotiated in the United made his recent appeal in letters to 17 pharmaceutical manufacturers, the White House announced last week. He asked them to reduce costs in the U.S. by matching the lowest prices of prescriptions drugs in other comparably developed countries. Some drugmakers have since indicated that they are open to cutting move follows an executive order Trump signed in May setting a 30-day deadline for drugmakers to electively lower prices in the U.S. or face new limits in the future over what the government will federal government has the most power to shape the price it pays for drugs covered by Medicare and Medicaid. It's unclear what - if any - impact the Trump administration's efforts will have on millions of Americans who have private health pointed out that if drug manufacturers had cut costs to the extent Trump claims, they would be shouting it from the rooftops, especially given the heat they've taken over the years for their pricing practices."My expectation would be that they would make announcements - public announcements - and that those announcements would come way in advance of the actual effective dates when those price cuts would come into effect," she agreed that there has been no indication of a substantial cut."Not at all, not at all, none whatsoever," he said. "And let alone 1,500."
